{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Atrasentan_Hydrochloride",
  "nciThesaurus": {
    "casRegistry": "195733-43-8",
    "chebiId": "",
    "chemicalFormula": "C29H38N2O6.ClH",
    "definition": "The orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity.  As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.",
    "fdaUniiCode": "E4G31X93ZA",
    "identifier": "C1779",
    "preferredName": "Atrasentan Hydrochloride",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C28334"
    ],
    "synonyms": [
      "(+)-A 127722",
      "(2R,3R,4S)-4-(1,3-Benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic Acid Monohydrochloride",
      "ABT-627",
      "ATRASENTAN HYDROCHLORIDE",
      "Atrasentan Hydrochloride",
      "Xinlay"
    ]
  }
}